Managing Anemia of Chronic Kidney Disease

Krikorian, Susan A.

doi:10.1177/1559827608327912

Cited by 2 publications

(2 citation statements)

References 72 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The kidneys produce erythropoietin which is involved in erythropoiesis, and therefore damage to the kidney impairs erythropoiesis and blood cell formation 38 . Damage to the glomerulus causes an increase in serum creatinine and urea levels as well as the presence of albumin in the urine 39 .…”

Section: Discussionmentioning

confidence: 99%

Acute and sub-chronic toxicity of aqueous stem-bark extract ofAnnickia polycarpa

Lartey,

Nyarko,

Asare-Anane

et al. 2023

Preprint

View full text Add to dashboard Cite

Background and aim: The lack of standardization and scientific validation of the use of most plant extracts leads to toxicity problems. The stem bark extract of Annickia polycarpa has been shown to possess antioxidant, antidiabetic, analgesic, and anti-colitis effects. However, nothing is known about the effects of the prolonged use of the extract. Thus, we investigated the acute and sub-chronic toxicity of the aqueous stem bark extract of (APE) in Sprague-Dawley rats. Experimental procedure: The LD50 and sub-chronic toxicity of APE (20 mg/kg, 100 mg/kg, and 500 mg/kg) was studied over 3 months in Sprague-Dawley rats. Serum alkaline phosphatase (ALP), alanine transaminase (ALT), direct bilirubin and creatinine were measured after 3 months of treatment. Hematological analysis and urinalysis were also performed. Also, the effect of APE on blood clotting time and pentobarbital-induced sleeping time were determined at the termination of treatment. Finally, histological analysis was done on the liver, kidney, lung, and heart after hematoxylin-eosin staining of tissue cross-sections at the termination of treatment. Results and conclusion: The LD50 of APE in rats was higher than 5000 mg/kg with no observable signs of toxicity. APE also showed no hematotoxic effect when used consistently for 3 months. Additionally, APE had no adverse effect on the liver and kidney evidenced by a lack of effect on serum biochemical parameters (ALP, ALT, direct bilirubin, and creatinine), urinalysis as well as the tissue morphology of these organs. No adverse morphological effects were also observed with the heart muscle cells. However, APE showed mild selective toxicity to the lung characterized by alveolar space closing, interstitial fibrosis, and alveolar septa thickening. These results indicate that APE is generally non-toxic at the tested doses but shows mild selective pneumotoxicity when used over a long period of time.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute and sub-chronic toxicity of aqueous stem-bark extract ofAnnickia polycarpa

Lartey,

Nyarko,

Asare-Anane

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Dengan penatalaksanaan anemia yang tepat maka dapat membantu meningkatkan kualitas hidup pasien (mengurangi gejala-gejala anemia) dan peningkatan kadar hemoglobin. Beberapa faktor pada penderita anemia disebabkan kondisi ginjal kronis temasuk turunnya eritropoetin oleh ginjal, pendeknya usia eritrosit, masalah malnutrisi, dan defisiensi zat besi, serta terhambatnya distribusi eritropoetin karena faktor lain Pada penelitian ini pengambilan sampel dilakukan dengan beberapa kriteria diantaranya pada pasien yang baru pertama kali menjalani hemodialisa, untuk melihat bagaimana pemberian jenis obat mempengaruhi kadar hemoglobin pada pasien (mendekati nilai normal) [9,10].…”

Section: Pendahuluanunclassified

ANALISIS TERAPI ANEMIA PADA PASIEN GAGAL GINJAL KRONIK DI RSUD Dr. DRADJAT PRAWIRANEGARA TAHUN 2022

Insani,

Zulfiani,

Yusransyah

2024

JIPP

View full text Add to dashboard Cite

Under normal circumstances, 90% of the kidneys produce the hormone erythropoietin which has the function of stimulating the spinal cord to produce red blood cells, so that when kidney function decreases, there is a decrease in the production of the hormone erythropoietin which causes the formation of erythrocytes to be disrupted, resulting in a decrease in hemoglobin levels or anemia. The aim of this study was to determine the therapy of anemia in patients with chronic kidney failure undergoing hemodialysis and to determine the results of anemia therapy in patients with chronic renal failure undergoing hemodialysis at RSUD Dr. Dradjat Prawiranegara Year 2022. The research was conducted using a retrospective descriptive method by looking at the medical record data of chronic kidney failure patients undergoing hemodialysis who were receiving anemia therapy. The sample in this study amounted to 80 patients. The data were then analyzed descriptively regarding the analysis of anemia therapy in hemodialysis chronic kidney failure patients. The results showed that the hemodialysis hemoglobin level examination found an average of 8.8 g/dL and was included in the range below the normal value of hemoglobin levels. The most use of anemia drug therapy in 2022 for mono therapy is the most PRC Transfusion of 1 mg Folic Acid combination in 39 patients (48.8%). Furthermore, in the combination therapy of anemia with Blood Supplementary Tablets combined with Folic Acid 1 mg in 17 patients (21.3%) and the use of folic acid 1 mg in 24 patients (30.0%).Keywords: Anemia, Chronic Kidney Failure, Hemodialysis, RSUD Dr. Dradjat Prawiranegara.

show abstract

Managing Anemia of Chronic Kidney Disease

Cited by 2 publications

References 72 publications

Acute and sub-chronic toxicity of aqueous stem-bark extract ofAnnickia polycarpa

Acute and sub-chronic toxicity of aqueous stem-bark extract ofAnnickia polycarpa

ANALISIS TERAPI ANEMIA PADA PASIEN GAGAL GINJAL KRONIK DI RSUD Dr. DRADJAT PRAWIRANEGARA TAHUN 2022

Contact Info

Product

Resources

About